Cedar Grove Capital Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Hims & Hers Health, Inc. (HIMS) closed the latest trading day at $27.23, indicating a +1.57% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...

Hims & Hers Health Inc. (HIMS) is facing increased skepticism from investors and analysts over the sustainability concerns of ...

As a federal crackdown on Ozempic-style copycats looms, Hims is trying a unique new strategy to lobby lawmakers.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.